CoChat
Sign Up
Cited by 229Antimicrobial agents and applicationsInfection Control in HealthcareInfection Control and Ventilation

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Rapid and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA).

Open access
Eggers, Maren, Eickmann, Markus, Zorn, Juergen·2015·Infectious Diseases and Therapy
DOI 10.1007/s40121-015-0091-9PMC PMC4675768
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV. METHODS: According to EN14476, a standard suspension test was used to assess virucidal activity against MVA and large volume plating was used for MERS-CoV. All products were tested under clean (0.3 g/L bovine serum albumin, BSA) and dirty conditions (3.0 g/L BSA + 3.0 mL/L erythrocytes), with application times of 15, 30, and 60 s for MVA, and 15 s for MERS-CoV. The products were tested undiluted, 1:10 and 1:100 diluted against MVA, and undiluted against MERS-CoV. RESULTS: A reduction in virus titer of ≥4 log10 (corresponding to an inactivation of ≥99.99%) was regarded as evidence of virucidal activity. This was achieved versus MVA and MERS-CoV, under both clean and dirty conditions, within 15 s of application of each undiluted PVP-I product. CONCLUSION: These data indicate that PVP-I-based hand wash products for potentially contaminated skin, and PVP-I gargle/mouthwash for reduction of viral load in the oral cavity and the oropharynx, may help to support hygiene measures to prevent transmission of MERS-CoV. FUNDING: Mundipharma Research GmbH & Co.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40121-015-0091-9

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. Yung D, Tang M. Press release: 10 years after SARS—improper hand washing in the majority of HK people coupled with a 25% drop in cold & flu sick leave for reducing risk of spreading of germs doctor urges to regain strict personal hygiene habits. 2013. http://hkupop.hku.hk/english/report/postSARS/content/resources/pr.pdf . Accessed July 2015.

Cited by

Sorted by citations

Items 201–229 of 229

Related

See all

Metadata

Authors
Eggers, M., Eickmann, M., & Zorn, J.
Affiliations
  • Philipps University of Marburg (DE)
  • Mundipharma (Germany) (DE)
Corresponding author
Zorn, Juergen
ORCID
Eggers, Maren
Venue
Infectious Diseases and Therapy
Publisher
Springer Science and Business Media LLC
Published
2015-09-28
Volume
4
Issue
4
Pages
491-501
ISSN
  • 2193-6382 (ISSN-L)
  • 2193-8229
DOI
10.1007/s40121-015-0091-9
PMC
PMC4675768
OpenAlex
W2106483552
Cited by
229
References
21
Citations by year
2026: 2 · 2025: 3 · 2024: 8 · 2023: 17 · 2022: 29 · 2021: 54 · 2020: 108 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 1
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Infectious Diseases and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Philipps-Universität Marburg
Topics
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
  • Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Infection Control and Ventilation
Keywords
povidone-iodine, MERS-CoV, modified vaccinia Ankara, virucidal activity, hand hygiene, surgical scrubbing, mouthwash, skin disinfection, viral load reduction, nosocomial transmission

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review